Show simple item record

dc.contributor.authorHultberg, Josabeth
dc.contributor.authorRudebeck, Carl Edvard
dc.date.accessioned2018-06-29T11:05:28Z
dc.date.available2018-06-29T11:05:28Z
dc.date.issued2017-02-28
dc.description.abstract<p><i>Objective</i>: The aim of the study was to describe and explore patient agency through resistance in decision-making about cardiovascular preventive drugs in primary care.</p> <p><i>Design</i>: Six general practitioners from the southeast of Sweden audiorecorded 80 consultations. From these, 28 consultations with proposals from GPs for cardiovascular preventive drug treatments were chosen for theme-oriented discourse analysis.</p> <p><i>Results</i>: The study shows how patients participate in decision-making about cardiovascular preventive drug treatments through resistance in response to treatment proposals. Passive modes of resistance were withheld responses and minimal unmarked acknowledgements. Active modes were to ask questions, contest the address of an inclusive we, present an identity as a non-drugtaker, disclose non-adherence to drug treatments, and to present counterproposals. The active forms were also found in anticipation to treatment proposals from the GPs. Patients and GPs sometimes displayed mutual renouncement of responsibility for decision-making. The decision-making process appeared to expand both beyond a particular phase in the consultations and beyond the single consultation.</p> <p><i>Conclusions</i>: The recognition of active and passive resistance from patients as one way of exerting agency may prove valuable when working for patient participation in clinical practice, education and research about patient–doctor communication about cardiovascular preventive medication. We propose particular attentiveness to patient agency through anticipatory resistance, patients’ disclosures of non-adherence and presentations of themselves as non-drugtakers. The expansion of the decision-making process beyond single encounters points to the importance of continuity of care.</p> <p><i>KEY POINTS</i></p> <p>Guidelines recommend shared decision-making about cardiovascular preventive treatment. We need an understanding of how this is accomplished in actual consultations.This paper describes how patient agency in decision-making is displayed through different forms of resistance to treatment proposals.</p> <p>The decision-making process expands beyond particular phases in consultations and beyond single encounters, implying the importance of continuity of care.</p> <p>Attentiveness to patient participation through resistance in treatment negotiations is warranted in clinical practice, research and education about prescribing communication.en_US
dc.descriptionSource at <a href=https://doi.org/10.1080/02813432.2017.1288814> https://doi.org/10.1080/02813432.2017.1288814</a>. Accepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0. </a>en_US
dc.identifier.citationHultberg, J. & Rudebeck, C.E. (2017). Patient participation in decision-making about cardiovascular preventive drugs – resistance as agency. Scandinavian Journal of Primary Health Care, 35(3), 231-239. https://doi.org/10.1080/02813432.2017.1288814en_US
dc.identifier.cristinIDFRIDAID 1519369
dc.identifier.doi10.1080/02813432.2017.1288814
dc.identifier.issn0281-3432
dc.identifier.issn1502-7724
dc.identifier.urihttps://hdl.handle.net/10037/13057
dc.language.isoengen_US
dc.publisherTaylor & Francis Openen_US
dc.relation.journalScandinavian Journal of Primary Health Care
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectCommunicationen_US
dc.subjectshared decision-makingen_US
dc.subjectpreventionen_US
dc.subjectcardiovascular drugsen_US
dc.subjectcardiovascular diseasesen_US
dc.subjectgeneral practiceen_US
dc.subjectqualitative researchen_US
dc.subjectSwedenen_US
dc.titlePatient participation in decision-making about cardiovascular preventive drugs-resistance as agencyen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record